Bluefish wins another tender auction in Spain
Exclusive supplier in new contract offers continued growth
Bluefish has been selected as the exclusive provider of three products in another contract with Servicio Andaluz de Salud (SAS), the state health authority in Spanish Andalusia. The new contract includes Almotriptan 12.5 mg, Bicalutamide 150 mg and Eplerenone 25 and 50 mg. Initial supply is planned for the end of 2015. The additional net sales value from the contract is estimated to approximately SEK 19 million per year.
The agreements with SAS add major growth potential for the company's operations in Spain. Even if one of the contracts expires at year-end, the value of net sales for the three remaining contracts valid during 2016 is expected to offer continued growth in net sales with a satisfactory gross margin. Operations in Spain is thus expected to make an important contribution to the company’s financial performance during 2016.
Bluefish also continues to invest in the Spanish product porfolio within areas that have interesting sales and earnings potential.
Bluefish has previously been selected as the semi-exclusive as well as the exclusive provider of a number of products to SAS. While tender auctions for pharmaceuticals are common practice throughout Europe, so far, Andalusia is the only one of Spain‘s 17 different regions where this method is applied.
Bluefish has successfully built market share in major European markets by offering high quality generic pharmaceuticals. Never compromising on product quality and patient safety, Bluefish markets products in an innovative, responsible and cost-efficient way with the ambition of making modern medicines accessible to more people. Bluefish is operating in a large number of European markets. The product portfolio consists of approximately 80 products and is growing.
For more information, contact
Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
Susanna Urdmark, CFO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of approximately 80 products and is growing.